Fatigue News and Research

RSS

New approach to identify molecules that prevent immune cells from attacking body

A study led by a Scripps Research Institute scientist describes a new, highly pragmatic approach to the identification of molecules that prevent a specific type of immune cells from attacking their host. The findings add a powerful new tool to the ongoing search for potential treatments for autoimmune diseases, such as multiple sclerosis (MS), as well as blood cancers, such as myeloid leukemia.

2 Dec 2009

Study examines role of low-oxygen exposure in heart failure patients

Distance runners who live at high altitudes with low oxygen levels are known to improve their performance during races in areas that are at sea level. Can heart failure patients, who suffer from fatigue, improve their exercise performance by staying in a tent-like, high-altitude simulator?

1 Dec 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Chiropractic treatment for TMJ dysfunction

When most people hear the acronym TMJ, they think of their dentist. But a chiropractor can also give patients the help they need. TMJ stands for the Temporal-Mandibular Joint, which is where your jaw (mandible) contacts/connects with your skull (temporal bone).

26 Nov 2009

UT Southwestern Medical Center to offer NeuRx Diaphragm Pacing System implantation

Physicians at UT Southwestern Medical Center soon will begin implanting a new device designed to improve breathing in patients with upper spinal-cord injuries or other diseases that keep them from breathing independently.

26 Nov 2009

Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc., today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York.

25 Nov 2009

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

Withheld anger in MS patients can have adverse effect on health

People with Multiple Sclerosis (MS) feel more than twice as much withheld anger as the general population and this could have an adverse effect on their relationships and health, according to a study published in the December issue of the European Journal of Neurology.

24 Nov 2009

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009

Study finds depressed or burned out surgeons more likely to commit major error on the job

Surgeons who are burned out or depressed are more likely to say they had recently committed a major error on the job, according to the largest study to date on physician burnout. The new findings suggest that the mental well-being of the surgeon is associated with a higher rate of self-reported medical errors, something that may undermine patient safety more than the fatigue that is often blamed for many of the medical mistakes.

23 Nov 2009

Early diagnosis and treatment is crucial for pulmonary hypertension, a rare but deadly disease

We often hear about the perils of high blood pressure, but many Canadians are unaware that high blood pressure in the lungs - known as pulmonary hypertension (PH) - can also have fatal consequences. This month, the Pulmonary Hypertension Association of Canada hopes to raise awareness about PH - a rare but serious disease that can strike at any time and has no regard for race, age or gender.

19 Nov 2009

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Exelixis, Inc. today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors.

19 Nov 2009

Canadian comedian helps raise awareness about COPD

COPD is no joke to Canadian comedian Mary Walsh. "It's shocking that so few Canadians know about COPD considering it's the fourth leading cause of death in this country," says Mary Walsh, spokesperson for The Canadian Lung Association.

18 Nov 2009

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information.

18 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009

Family caregivers can reduce suffering in cancer patients through simple touch and massage techniques

Family caregivers can significantly reduce suffering in cancer patients at home through use of simple touch and massage techniques. These findings were recently reported at the 6th International Conference of the Society for Integrative Oncology.

18 Nov 2009

Improved productivity and lowered absenteeism are top priorities for business leaders

Improving productivity by keeping employees healthy and working is emerging as the top business objective for employer-sponsored wellness programs around the world. The two exceptions are the United States, where reducing health care cost increases overwhelmingly continues to be the top goal, and Asia, where the most important objective is improving workforce morale.

17 Nov 2009

Additional vaccine for 2009 H1N1 flu approved by FDA

The U.S. Food and Drug Administration announced that it has approved a fifth vaccine for protection against the 2009 H1N1 influenza virus. The vaccine is manufactured by ID Biomedical Corp. of Quebec, Canada, owned by GlaxoSmithKline PLC.

16 Nov 2009

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).

16 Nov 2009

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

Fatigue News and Research

New approach to identify molecules that prevent immune cells from attacking body

Study examines role of low-oxygen exposure in heart failure patients

Eli Lilly's Cymbalta receives FDA approval

Chiropractic treatment for TMJ dysfunction

UT Southwestern Medical Center to offer NeuRx Diaphragm Pacing System implantation

Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Withheld anger in MS patients can have adverse effect on health

Lysteda tablets to treat menorrhagia approved by the FDA

Study finds depressed or burned out surgeons more likely to commit major error on the job

Early diagnosis and treatment is crucial for pulmonary hypertension, a rare but deadly disease

Interim data from an ongoing phase 1 dose-escalation trial of XL147 reported

Canadian comedian helps raise awareness about COPD

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

NeoPharm presents LE-DT Phase I data at the AACR conference

Family caregivers can reduce suffering in cancer patients through simple touch and massage techniques

Improved productivity and lowered absenteeism are top priorities for business leaders

Additional vaccine for 2009 H1N1 flu approved by FDA

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

FDA approves Lysteda for treating menorrhagia

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News